AUPH

Aurinia Pharmaceuticals
AUPH

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$1.11B
EV
$832.00M
Shares Outstanding
137.34M
Beta
1.21

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$9.83
P/E 2025E
17.40x
P/Revenue 2025E
4.30x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Aurinia Pharmaceuticals Inc.

gainify
AUPH

Aurinia Pharmaceuticals Inc.

AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active l...

Sector

Healthcare

Industry

Biotechnology

CEO

Greenleaf, Peter

Employees

130

IPO Date

2014-09-03

Headquarters

118 Avenue 14315, Suite 140, Edmonton, Alberta, T5L 4S6, Canada

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved